IPP Bureau
GSK registers 5% revenue growth in Q2 FY24
By IPP Bureau - November 10, 2023
General Medicine grows 5% and Vaccines 10% led by Shingrix
SMS Pharmaceuticals reports robust Q2FY24 operational performance
By IPP Bureau - November 10, 2023
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Intermountain Health files complain against Dr. Reddy’s and others
By IPP Bureau - November 10, 2023
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr
By IPP Bureau - November 10, 2023
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
BASF Pharma, IFF Pharma collaborate on virtual assistant platform ZoomLab
By IPP Bureau - November 09, 2023
The collaboration brings a seamless digital experience to more formulators worldwide
Lupin launches Rocuronium Bromide injection in US
By IPP Bureau - November 09, 2023
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Bayer posts Q3 2023 Group sales Euro 10.34 billion
By IPP Bureau - November 09, 2023
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Biocon Biologics announces divestment of two non-core branded formulations
By IPP Bureau - November 09, 2023
Total transaction value of the divestment is Rs. 3,660 million
Evonik launches GMP-quality plant-based squalene
By IPP Bureau - November 08, 2023
PhytoSquene now available for clinical and commercial use
Indian pharmaceutical companies have become reliable and affordable suppliers of high-quality drugs: MoS Bhagwant Khuba
By IPP Bureau - November 08, 2023
Lack of technology transfer stands out as a formidable barrier
Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr
By IPP Bureau - November 08, 2023
Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets
By IPP Bureau - November 08, 2023
This product will be manufactured at Lupin’s Pithampur facility in India
Gland Pharma posts Q2 FY24 consolidated PAT at Rs. 194.08 Cr
By IPP Bureau - November 07, 2023
Gland Pharma has reported total income of Rs. 1426.57 crores during the period ended September 30, 2023
Sun Pharma Advanced Research posts Q2 FY24 loss at Rs. 86.42 Cr
By IPP Bureau - November 07, 2023
Sun Pharma Advanced Research Company Limited has reported total income of Rs. 29.67 crores during the period ended September 30, 2023
Max Healthcare Institute reports Q2 FY24 consolidated PAT at Rs. 276.68 Cr
By IPP Bureau - November 07, 2023
Max Healthcare Institute has reported total income of Rs. 1408.64 crores during the period ended September 30, 2023
